FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia

Investigational Dyskinesia Treatment Gets FDA Green Light

VistaGen to study dyskinesia drug in Phase II Parkinson’s trial

FDA Clears Study to Test New Drug to Treat Dyskinesia for Parkinson Patients

Intranasal Therapy Fast-Tracked for Social Anxiety Disorder

Long-Term Use of Benzodiazepines – Avoiding Another Drug Crisis

Advancing AV-101

PH10 – Nasal spray that works like spritzers to the brain

Living with Social Anxiety Disorder: Uncovering Next – Generation Treatments for a Common and Debilitating Mental Illness